Literature DB >> 24807232

Prevention and treatment of injection-related endophthalmitis.

Charles Q Yu1, Christopher N Ta.   

Abstract

BACKGROUND: Intravitreal injections are the fastest growing cause of endophthalmitis and can result in severe vision loss. The prevention, diagnosis and management of such infections remain unclear and at times controversial.
METHODS: We searched Pubmed for keywords "prophylaxis," "endophthalmitis," "intravitreal injection." We focused on studies published in the last 2 years as well as other recent studies with particular attention to data on the incidence, microbiology, prevention, and treatment of injection-related endophthalmitis.
RESULTS: Over 20 relevant studies were found. With povidone-iodine preparation, the per-injection endophthalmitis rate is low at about 0.03%. Antibiotics do not appear to be beneficial for prevention of post-injection endophthalmitis. The best timing of vitrectomy is unclear.
CONCLUSIONS: Antibiotic prophylaxis is probably not needed when giving intravitreal injections. More data is needed to help determine the proper treatment for post-injection endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24807232     DOI: 10.1007/s00417-014-2644-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  29 in total

1.  Quality of bevacizumab compounded for intravitreal administration.

Authors:  J M Palmer; W M Amoaku; F Kamali
Journal:  Eye (Lond)       Date:  2013-06-21       Impact factor: 3.775

2.  Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes.

Authors:  Matthew P Simunovic; Ryan B Rush; Alex P Hunyor; Andrew A Chang
Journal:  Br J Ophthalmol       Date:  2012-03-24       Impact factor: 4.638

Review 3.  Intravitreal injections: a review of the evidence for best practice.

Authors:  Xavier J Fagan; Salmaan Al-Qureshi
Journal:  Clin Exp Ophthalmol       Date:  2013-07       Impact factor: 4.207

4.  Changes in ocular flora in eyes exposed to ophthalmic antibiotics.

Authors:  Sarita B Dave; Hassanain S Toma; Stephen J Kim
Journal:  Ophthalmology       Date:  2013-02-13       Impact factor: 12.079

5.  Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.

Authors:  Ross J Brechner; Philip J Rosenfeld; J Daniel Babish; Stuart Caplan
Journal:  Am J Ophthalmol       Date:  2011-02-18       Impact factor: 5.258

6.  Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.

Authors:  Colin A McCannel
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

7.  Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask.

Authors:  Hiroyuki Shimada; Takayuki Hattori; Ryusaburo Mori; Hiroyuki Nakashizuka; Kyoko Fujita; Mitsuko Yuzawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

8.  Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.

Authors:  Abdhish R Bhavsar; Joseph M Googe; Cynthia R Stockdale; Neil M Bressler; Alexander J Brucker; Michael J Elman; Adam R Glassman
Journal:  Arch Ophthalmol       Date:  2009-12

9.  Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection.

Authors:  Khurram M Chaudhary; Juan M Romero; Isaac Ezon; David M Fastenberg; Vincent A Deramo
Journal:  Retina       Date:  2013 Jul-Aug       Impact factor: 4.256

10.  Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.

Authors:  Miriam Englander; Teresa C Chen; Eleftherios I Paschalis; Joan W Miller; Ivana K Kim
Journal:  Br J Ophthalmol       Date:  2013-02-06       Impact factor: 4.638

View more
  6 in total

1.  Comment on bilateral same-session intravitreal injections.

Authors:  Levent Karabas; Fehim Esen; Ozlem Sahin
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

2.  Postoperative endophthalmitis incidence after intravitreal therapy: a comparison of two different preoperative antibiotic prophylaxis.

Authors:  Sergio Piscitello; Maria Vadalà
Journal:  Int Ophthalmol       Date:  2016-09-01       Impact factor: 2.031

3.  Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms.

Authors:  Mira M Sachdeva; Ala Moshiri; Henry A Leder; Adrienne W Scott
Journal:  J Ophthalmic Inflamm Infect       Date:  2016-01-12

4.  Acute bacterial endophthalmitis following intravitreal dexamethasone implant: A case report and review of literature.

Authors:  Neha Goel
Journal:  Saudi J Ophthalmol       Date:  2016-12-18

Review 5.  Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections.

Authors:  P Et Lau; K S Jenkins; C J Layton
Journal:  J Ophthalmol       Date:  2018-07-24       Impact factor: 1.909

6.  Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach.

Authors:  Anne-Sofie Petri; Kirstine Boysen; Lasse J Cehofski; Elon H C van Dijk; Chantal Dysli; Josefine Fuchs; Rodolfo Mastropasqua; Yousif Subhi
Journal:  Ophthalmol Ther       Date:  2020-02-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.